The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: October 2011

Friday Science Review: October 21, 2011

CD34: Beyond A Stem Cell Marker Biomedical Research Centre, Vancouver ♦ University of British Columbia ♦ Sprott Centre for Stem Cell Research, Ottawa ♦ Others.. Published in Stem Cells, October 13, 2011 Despite the fact that the cell surface marker CD34 is typically used to identify a diversity of adult stem cell types, no regeneration-related [...]

Monday Biotech Deal Review: October 17, 2011

Welcome to your Monday Biotech Deal Review for October 17, 2011.  This week’s deal review is a double feature following last Monday’s Canadian thanksgiving holiday.  Of note from the past two weeks were the acquisition of Labopharm by Paladin Labs, and its announcement that it is ceasing its hostile takeover pursuit of Afexa. 

Friday Science Review: October 14, 2011

Ubiquitin Ligase Sweeps Aggregates University of British Columbia ♦ Published in Nature Cell Biology, October 9, 2011 It seems that ubiquitin ligase may play a critical role in preventing diseases characterized by protein aggregation. The enzyme acts by fusing a polyubiquitin chain to misfolded proteins that sit in the cytoplasm. Once tagged, these faulty proteins [...]

Assessing Potential Market Share for a New Drug: Part 14 of Valuation and Other Biotech Mysteries

[Ed. This is the fourteenth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] In the previous post, we looked at epidemiology and pricing to estimate the market size for a new [...]

Potential Rewards from Successful Drug Development: Part 13 of Valuation and Other Biotech Mysteries

[Ed. This is the thirteenth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] Finally we have reached the point of looking at the potential rewards from successful drug development. The potential [...]

Friday Science Review: October 7, 2011

Cell Polarity Dictated by Phosphatidylserine Hospital for Sick Children ♦ Published in Nature Cell Biology, October 2, 2011 The enzyme Cdc42 is responsible in part for cell polarization during asymmetric cellular events. In the case of the yeast S. cerivisiae, polarization is essential during the process of budding and the formation of projections in response [...]

Monday Biotech Deal Review: October 3, 2011

Welcome to your Monday Biotech Deal Review for October 3, 2011.  Last week witnessed a flurry of financing activity, with over $50M closed.  As well, the competing take-over bids between Paladin and Valeant for Afexa heated up with both Valeant and Paladin sweetening their offers to Afexa shareholders.  Read on to learn more. 

Follow

Get every new post delivered to your Inbox.

Join 76 other followers